Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced positive results from a study assessing a new lower-volume injection of Copaxone ® (glatiramer acetate) ...
The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
JERUSALEM--(BUSINESS WIRE)--Jul. 26, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S.
This is the first cost-effectiveness model comparing COPAXONE ® and Tysabri ® for treatment of multiple sclerosis (MS) to take into consideration long-term treatment outcomes, where available, effects ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results